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Chronic inflammatory process in the nasal mucosa is correlated with poor smell
perception. Over-activation of immune cells in the olfactory epithelium (OE) is generally
associated with loss of olfactory function, and topical steroidal anti-inflammatory drugs
have been largely used for treating such condition. Whether this therapeutic strategy
could directly affect the regenerative process in the OE remains unclear. In this study,
we show that nasal topical application of dexamethasone (DEX; 200 or 800 ng/nostril),
a potent synthetic anti-inflammatory steroid, attenuates OE lesion caused by Gram-
negative bacteria lipopolysaccharide (LPS) intranasal infusion. In contrast, repeated DEX
(400 ng/nostril) local application after lesion establishment limited the regeneration of
olfactory sensory neurons after injury promoted by LPS or methimazole. Remarkably,
DEX effects were observed when the drug was infused as 3 consecutive days
regimen. The anti-inflammatory drug does not induce OE progenitor cell death, however,
disturbance in mammalian target of rapamycin downstream signaling pathway and
impairment of protein synthesis were observed during the course of DEX treatment.
In addition, in vitro studies conducted with OE neurospheres in the absence of an
inflammatory environment showed that glucocorticoid receptor engagement directly
reduces OE progenitor cells proliferation. Our results suggest that DEX can interfere
with the intrinsic regenerative cellular mechanisms of the OE, raising concerns on the
use of topical anti-inflammatory steroids as a risk factor for progressive olfactory function
impairment.
Keywords: anosmia, inflammation, corticoids, innate immune response, neurogenesis, neuronal cell death,
S6 kinase, Toll-like receptor 4
Abbreviations: CHX, cycloheximide; CNS, central nervous system; DEX, dexamethasone; DEX-BSA, dexamethasone
conjugated to bovine serum albumin; Div, days in vitro; Dpl, days post-lesion; GC, glucocorticoid; GR, glucocorticoid
receptor; LPS, lipopolisaccharide; OE, olfactory epithelium; OMP, olfactory marker protein; OSN, olfactory sensory neuron;
PCNA, proliferating cell nuclear antigen; S6K1, p70-S6 ribosomal kinase; TLR, Toll-like receptor.
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INTRODUCTION
Chronic rhinosinusitis is one of the most common inflammatory
condition in the upper respiratory tract, a fact corroborated by
the estimated proportion of affected individuals, 5–15% of the
general population (Holbrook and Leopold, 2006; Bachert et al.,
2014). Considering that roughly 14–30% of nasosinus disease
patients present olfactory dysfunction (Holbrook and Leopold,
2006), it is possible to estimate that dozens of people in every
thousand can present some degree of loss of sense of smell due
to nasal mucosa chronic inflammation.
The OE, the tissue that transduces odorant signals into
neuronal activity, is found on the nasal septum and on a series
of turbinates in the posterior region of the nasal cavity (Mori and
Sakano, 2011; Ihara et al., 2013). Mature OSNs are OE bipolar
cells that transduce odorant signaling from the epithelial surface
to the olfactory bulb of the brain (Graziadei and Monti-Graziadei,
1979). The OE is subjected to self-renewal throughout life due to
the relatively short average life span of OSNs (Mackay-Sim and
Kittel, 1991). Neuronal progenitors denominated globose cells
(GBCs), which are located adjacent to the OE basal membrane,
replenish the OSNs in a regular basis. However, horizontal basal
cells (HBCs), the prototypical stem-cell of the OE, are recruited
upon massive neuronal cell death in the OE in order to generate
a large number of OSNs (Leung et al., 2007; Iwai et al., 2008),
making the OE a remarkable site of adult neurogenesis (Brann
and Firestein, 2014).
A significant decrease in quality of life is associated with loss
of the sense of smell, including decreased appetite, depression,
spoiled food consumption, and unawareness of potential danger
signals such as smoke and exposure to dangerous chemicals;
overall reducing psychological wellbeing (Blomqvist et al., 2004;
Croy et al., 2014). It has been suggested that the extent of olfactory
recovery depends on the duration of olfactory loss (London
et al., 2008), implying that treatment strategies may impact the
clinical outcome if the natural regenerative process is accelerated
or delayed. Hence, it is a reasonable assumption that olfactory
loss due to OE cells damage could be more or less permanent
depending on the velocity of OSNs replenishment.
Acute models of OE lesion are valuable paradigms
characterized by substantial and fast regeneration of OSNs,
offering a straightforward procedure to evaluate if specific
chemical compounds and biomolecules impair or enhance the
neural cells replenishment. For instance, an analogous approach
has been used for evaluating the impact of brain inflammation on
oligodendrocyte repopulation after acute demyelination (Glezer
et al., 2006; Franklin and Ffrench-Constant, 2008), and on CNS
neurogenesis (Monje, 2003; Ekdahl et al., 2009). In this study, we
show that engagement of innate immune response by bacterial
LPS can be used as an inflammatory acute model of cell death in
the OE. It is well characterized that LPS triggers TLR4 activation
on the surface of myeloid cells, activating the transcription of
several pro-inflammatory genes through nuclear factor kappa-B
(NF-κB) and AP-1 transcription factors (Aderem and Ulevitch,
2000). GCs engage GRs and interfere at multiple levels with NF-
κB/AP-1 pathway and the expression of pro-inflammatory genes.
GCs have been successfully used for several decades for treating
inflammatory diseases (Tsurufuji et al., 1979; Scheinman et al.,
1995; Almawi et al., 1996; De Bosscher et al., 2003; Xavier et al.,
2016). In fact, intranasal administration of GCs is considered
one of the most effective treatment for rhinosinusitis and nasal
polyposis (Avery, 1998; Meltzer et al., 2000; Parikh et al., 2001;
Csomor et al., 2013; Fandino et al., 2013).
We first aimed to verify whether topically infused synthetic
GC DEX, a strong and highly selective GR agonist devoid of
mineralocorticoid effect (Rosewicz et al., 1988; De Bosscher et al.,
2000), is able to protect the OE against acute inflammatory
injury. Using an effective DEX dose compatible with the known
therapeutic range, we investigated if the corticoid improves or
interferes with OE regeneration and an associated mechanism.
GCs have also been shown to interfere with protein synthesis
(Wang et al., 2006; Shimizu et al., 2011) and neural stem cell
proliferation (Samarasinghe et al., 2011). Mammalian target
of rapamycin (mTOR) signaling pathway is a major positive
modulator of both biological processes (reviewed in Russell
et al., 2011; Saxton and Sabatini, 2017). In consequence, we also
investigated whether GR signaling in OE affects mTOR pathway
and protein synthesis during early events involved in olfactory
regeneration at nasal mucosa level.
MATERIALS AND METHODS
Animal Experimentation
Newborn (P1–P3) or 3 months old adult male C57Bl/6 mice
(body weight, 25–29 g) from either biotério do Conjunto das
Químicas (Universidade de São Paulo) and Laboratório de
Experimentação Animal – Instituto Nacional de Farmacologia e
Biologia Molecular (Universidade Federal de São Paulo) were
acclimated to standard laboratory conditions (12/12 h light/dark
cycle; lights on at 6:00 AM and off at 18:00 PM), with ad libitum
access to rodent chow and water. This study was carried out in
accordance with animal experimentation procedures approved
by the local Committees (COBEA – USP, CEP – UNIFESP, and
CEUA – UNIFESP).
Intranasal Infusion
Mice were anesthetized under isoflurane gas and 10 µl of
vehicle (sterile 0.9% saline) or LPS (O55:B5 Sigma–Aldrich R©;
10 ng/µl) was infused with a PE-10 cannula (Braintree
Scientific, Inc., MA, United States) by means of a microinjection
pump with flow rate set to 4 µl/min. Intranasal infusions of
thionine or bromophenol blue solutions in anesthetized animals,
performed as terminal procedure, provided dye labeling used
to optimize drug delivery and visualize solution distribution
over the OE. For evaluation of anti-inflammatory effects,
DEX (injectable dexamethasone-phosphate; ACHÉ Laboratórios,
Brazil) was diluted to 20–80 ng/µl solutions in vehicle, which
were infused as described above. Unless otherwise specified,
only the right nostril was treated. For puromycin labeling
of protein synthesis, animal received intranasal infusion of
saline containing puromycin (100 ng/µl) 6 h after DEX
topical application for each time-point. Labeling specificity
was confirmed by CHX (10–1000 ng/µl) infusion 30 min
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FIGURE 1 | Topical DEX reduces OE injury provoked by LPS intranasal infusion. The panel depicts the OE of control or LPS-treated animals, as delimited by
arrowheads (A–P). (A,E,I,M) Low magnification photomicrographs of DAPI-stained sections, revealing significant OE atrophy due to cell loss caused by the TLR4
agonist. These histological changes correlate with loss of OMP staining (E–H). DEX, co-infused with LPS at the concentration of 20 or 80 ng/µl, as indicated,
dose-dependently prevented the cell loss associated with the inflammatory lesion (I–P). (D,H,L,P) Merged images of DAPI nuclear staining and OMP labeling.
It should be noted that A, E, I, and M are not necessarily matched to high magnification photomicrographs. (Q) Mean optical density from OE sections labeled with
antibody against the neuronal marker OMP. (R) OE cell layer thickness measures. Results represent means ± SEM of three mice per group. One-way ANOVA
[F (3,8) = 627, p < 0.0001 for OD; F (3,8) = 509, p < 0.0001 for OE thickness] followed by a Tukey’s HSD multiple comparison test: significantly different
(∗∗p < 0.001, ∗∗∗p < 0.0005) from the saline-treated animals; significantly different (#p < 0.0005) from the LPS-treated group. Scale bars: 300 µm for low
magnification pictures and 50 µm for all the others.
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FIGURE 2 | DEX treatment impairs OE regeneration after nasal injury mediated by LPS. Low magnification photomicrographs of DAPI-stained section revealing
partial OE regeneration 10 days after LPS infusion (A). Significant impairment of OSNs replenishment was observed when DEX (40 ng/µl) was infused three times,
once a day, starting 48 h after LPS intranasal administration. (C,G) The photomicrographs represent main differences in OMP expression between the groups. It is
also possible to note that DEX treatment promoted histological anomalies, but only in the LPS/DEX(3×)-treated group (E–H). (D,H) Merged images of DAPI nuclear
staining and OMP labeling. (I) OE cell layer thickness measures. (J) Mean optical density from OE sections labeled with the neuronal marker OMP. Results represent
thickness means ± SEM of three mice per group. Statistical scores were obtained with Student’s t-test (p < 0.05 in I and J). Scale bars: 300 µm for low
magnification pictures and 150 µm for all the others. Dashed squares indicate regions magnified for photomicrographs in B–D and F–H. White arrowheads indicate
morphologically compromised region; white asterisks indicate nerve bundles.
in advance of puromycin infusion. For optimal puromycin
labeling, the nostril was cleared with saline infusion prior to
puromycin application. Rapamycin was infused at 50 ng/µl
concentration.
Systemic Methimazole Treatment
Combined to Intranasal Infusion
The animals received either vehicle (sterile water) or
methimazole (50 mg/kg) at the first and fourth day of
experimentation as previously described (Bergman et al.,
2002). This treatment causes total loss of OMP-positive OSNs
and was found to be highly reproducible among animals. For
the evaluation of DEX effects on OE regeneration, intranasal
infusions of DEX (40 ng/µl) or vehicle were performed 24 h after
the second injection of the methimazole, either as a single dose
of DEX or for three consecutive doses every 24 h. Animals were
subjected to euthanasia at time-points 1, 2, 3, or 14 days after the
second injection of methimazole. In order to evaluate DEX effect
in early time-points (1–3 days), animals were euthanized 6 h after
the last intranasal infusion. For puromycin labeling, animals
were euthanized 30 min after the antibiotic application. In
case of experiments for immunoblotting, both nostrils received
intranasal infusions.
In Vivo Bromodeoxyuridine (BrdU)
Labeling for Fate Mapping
Mice subjected to methimazole treatment (starting at
experimental day 0) received i.p. injections of BrdU (50 mg/kg)
two times per day (∼8:00 AM and ∼6:00 PM). BrdU injections
started 72 h after the first methimazole administration
(experimental day 3), and ceased (i.e., last injection) 3 days
after the second methimazole administration (experimental
day 6). Animals were euthanized 14 days after the second
methimazole administration.
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FIGURE 3 | DEX short-term treatment, but not single-day treatment, impairs OE regeneration after OSNs loss induced by methimazole. Animals were treated with
methimazole (50 mg/kg; two doses, 2 days a part) and sacrificed 14 days after the second intraperitoneal administration of the damaging compound. OMP-stained
sections (A–D) from the OE reveal impaired cellular replenishment in topical DEX (40 ng/µl) 3 days-treated group (C,D) compared to the control animals (A,B).
(B,D) DNA staining with DAPI was merged to OMP in order to identify the OE cell layer. Mean optical density from OE sections labeled with the neuronal marker OMP
(E) and OE cell layer thickness measurements (F) reveal that 1-day single DEX treatment, 24 h after the second injection of methimazole (1 dpl), increases OE
thickness compared to the OE of mice that did not receive DEX. One-way ANOVA (F (2,6) = 13.2, p < 0.005 for OD; F (2,6) = 101, p < 0.0001 for OE thickness)
followed by a Tukey’s HSD multiple comparison test: significantly different (∗p < 0.05, ∗∗p < 0.0005) from saline-/methimazole-treated animals. Scale bars: 50 µm.
White arrowheads delimitate the OE.
Tissue Preparation
Animals were deeply anesthetized via an intraperitoneal
injection of a mixture of ketamine hydrochloride and xylazine
(300:30 mg/kg of ketamine/xylazine) and then rapidly perfused
transcardially with 0.9% saline, followed by 4% formaldehyde in
phosphate-buffered saline (PBS) pH 7.6, at 4◦C. The noses were
rapidly dissected, post-fixed, and decalcified for 2–4 weeks in 2%
formaldehyde/0.25 M EDTA, and then placed in 20% sucrose
complemented solution overnight at 4◦C for cryoprotection. The
nostrils were embedded in O.C.T. media and 16 µm coronal
sections were cut on a cryostat (Microm). The slices were
collected onto superfrost slides (Fisher Scientific), or equivalent,
and stored at −20◦C. A set of animals were perfused only with
cold saline and OE was quickly dissected, snap-frozen, and stored
at−80◦C for immunoblotting.
Immunoblotting
The tissue was homogenized in ice-cold lysis buffer (50 mM
Tris–HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 1 mM EDTA, 16 µg/ml benzamidine-HCl,
10 µg/ml phenanthroline, 10 µg/ml aprotinin, 10 µg/ml
pepstatin A, 10 µg/ml leupeptin, 1 mM PMSF, 10 mM sodium
fluoride, 1 mM sodium orthovanadate, 17.5 mM sodium beta-
glycerophosphate, and 6 mM sodium pyrophosphate) with
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FIGURE 4 | Fate-mapping of OE progenitor cells labeled with BrdU during lesion establishment and DEX treatment. Mice were treated with methimazole (two doses,
2 days a part) in order to provoke OSNs cell death, and euthanized 14 days after the second administration of methimazole (i.e., 14 dpl). The animals received BrdU
i.p. injections twice a day as represented over the time-scale (A). Animals that received intranasal DEX 40 ng/ml per day at 1, 2, and 3 dpl showed a pronounced
decrease number of BrdU-stained cells compared to their controls (B–G). BrdU-labeled cells were found to express OMP in a significant fraction of cells
(D,G) supporting decreased neurogenesis from precursor cells treated with DEX and revealing that the corticoid did not change the neuronal cell fate.
(H) Quantification of the number of BrdU-positive cells in the OE, (I) mean O.D. of OMP staining. Results represent thickness means ± SEM of three mice per group.
Statistical scores were obtained with Student’s t-test. Scale bar: 50 µm.
the aid of a microcentrifuge-compatible generator (Polytron R©–
Kinematica, Switzerland) to yield whole extracts. After debris
clearing by centrifugation, protein concentration was determined
using Bradford assay (Bio-Rad). The extracts were resolved
in SDS–PAGE and transferred by electrophoresis onto PVDF
membranes. For immunoblotting, membranes were blocked with
5% non-fat dry milk in Tween–Tris-buffered saline and then
incubated in the same buffer with the following antibodies:
anti-phospho-p70 S6 Kinase (Cell Signaling No. 9206), anti-
PCNA (Abcam No. ab29), anti-OMP (WAKO No. 544-10001),
and anti-β-actin (Millipore No. MABT523) or anti-eIF2alpha
(Cell Signaling No. 5324) as loading controls. Membranes were
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FIGURE 5 | DEX promotes reduced OE progenitor cell-cycling activity
triggered by injury. DEX or saline were infused in mice nostrils after
methimazole lesion, according to a 3-day repeated treatment, once a day,
starting from 1 dpl. The animals were subjected to euthanasia 6 h after the
third intranasal infusion. DAPI nuclear staining combined to Ki-67
immunostaining, used here as an index of cell division and proliferative activity,
showed reduced number of positive cells lining the OE lamina basal in case of
DEX treatment (A–F). The cell counting was adjusted to linear extension of
OE-selected regions (G). Results represent means ± SEM. Statistical scores
were obtained with Student’s t-test. Scale bar: 15 µm.
washed with Tween–Tris-buffered saline six times for 5 min and
then incubated with 1:10,000 secondary horseradish peroxidase-
conjugated antibody (Jackson ImmunoResearch, Inc.) for 1 h.
Following washing, immunoreactive bands were detected by
SuperSignalTM West Pico PLUS Chemiluminescent Substrate
(Thermo Scientific No. 34580) and captured using a LumiBis
DNR Bio-Imaging Systems device. Image densitometric analyses
were performed with the aid of ImageJ software1.
Neurosphere Generation and in Vitro
Differentiation
Neurosphere preparation from rodent OE has been previously
reported (Krolewski et al., 2011). Freshly dissected OE from
eight newborn (1–3-day-old) mice were pooled and submitted
to enzymatic dissociation with trypsin–EDTA 0.25% incubation
for 10 min at 37◦C. Trypsin was inactivated with 10% fetal
bovine serum supplemented media and cells were mechanically
dissociated with the aid of a micropipette. The suspensions were
passed through a 40-µm cell strainer (FalconTM) and centrifuged
for 5 min at 143× g. The supernatant was discarded and the pellet
was suspended in DMEM/F12 supplemented with 1% penicillin,
1% streptomycin, 2% B-27 (GibcoTM), and 20 ng/ml of either
EGF and FGF-2 (Sigma–Aldrich R©). Viable cells were counted for
plating at 2 × 105 density in 24-well plates coated with poly-
HEMA (Sigma–Aldrich R©), and incubated with drugs at standard
cell culture conditions (37◦C, 5% CO2, and ∼85% humidity) for
6–7 days, when OE neurospheres were unequivocally identified
in suspension. Spheroid counting was performed in 10 random
microscope fields, and replicates of the same treatment were
averaged. We only considered for analysis neurospheres with
diameter >25 µm. DEX was used in concentrations ranging
from 0.3 to 3 µg/ml, DEX–BSA was acquired from Steraloids
(Newport, RI, United States) and used at equivalent molar
concentration of DEX 1 µg/ml (∼2.12 µM), and mifepristone
(RU486) was used at 2.55 µM.
In order to validate olfactory identity of the culture, OE
neurospheres were differentiated into olfactory neurons. The
spheroids were centrifuged for 5 min at 143 × g, resuspended
in growth factor-deprived medium, and transferred onto 13 mm
poly-lysine/laminin-coated coverslips. The neurospheres were
allowed to differentiate in standard cell culture conditions for
7–14 days in the absence of growth factors, and subsequently
differentiated cells were prepared for OMP immunostaining.
Immunofluorescence
Phosphate-buffered saline-washed sections were blocked for
30 min with PBS containing 4% donkey serum, 1% BSA, and
0.4% Triton X-100. Using the same buffer solution composition,
the sections were incubated for ∼16 h at 4◦C with primary
antibody (polyclonal goat anti-OMP, WAKO No. 544-10001;
anti-Ki67, Abcam No. ab15580; and anti-puromycin, Millipore
No. MABE343). OE sections were washed three times with PBS
and primary antibody detection was conducted with compatible
Alexa Fluor R©-488 and -546 secondary antibodies (Molecular
Probes R©) in PBS/0.4% TritonTM X-100/1% BSA for 90 min.
1http://rsbweb.nih.gov/ij/
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FIGURE 6 | Topical DEX is not associated with increase in TUNEL-positive cells in injured OE. TUNEL labeling for DNA breaks was used as an index of cell death.
Methimazole-lesioned OE did not show increase in TUNEL-positive cells upon the GC treatment (ANOVA F (1,12) < 1 × 10−6, p = 0.9994). We failed to detect
changes at 1, 2, or 3 dpl (A–F,I). In order to validate the technic, we used 24 h methimazole single bolus administration as positive control (G,H), which showed
several positive nuclei. The cell counting was adjusted to linear extension of OE-selected regions (I). Results represent means ± SEM. Scale bar: 20 µm. White
arrows show few TUNEL-positive nuclei.
Sections were then rinsed with PBS and counterstained with
DAPI for nuclear labeling. For BrdU labeling, tissue sections were
pretreated with HCl 2 M for 30 min at 37◦C, washed several
times, and incubated with mouse anti-BrdU conjugated with
Alexa Fluor R©-555 (Molecular Probes R©). In the case of double-
labeling of BrdU and OMP, both antibodies were incubated after
HCl denaturation.
Differentiated neurospheres were washed with Dulbecco’s PBS
and fixed with cold PBS-buffered formaldehyde 2% for 15 min.
The coverslips were rinsed three times with PBS and blocked
with PBS/0.1% TritonTM X-100/10% horse serum for 1 h. The
fixed material was incubated anti-OMP in blocking solution for
15 h at 4◦C. After three PBS wash steps, secondary detection was
performed with anti-goat conjugated with Alexa Fluor R©-546 or
-555.
Terminal Deoxynucleotidyl Transferase
dUTP Nick-End Labeling (TUNEL)
Tissue sections were labeled for cleaved DNA detection with
In Situ Cell Death Detection Kit-TMR red (Roche) according to
manufacturer instructions.
Image Processing
Photomicrographs were acquired with epifluorescence
microscopes (Nikon R© or Carl Zeiss) or confocal microscopes
(Carl Zeiss or Leica). The images were processed to enhance
contrast and image quality using GIMP2 and were assembled
using Inkscape3. The image edition was kept to a minimum to
avoid artifacts, and equivalent treatment was applied to pictures
representing different groups.
Image Analysis
For cell layer thickness measures, photomicrographs were
analyzed directly with AxioVision (Carl Zeiss) image capture
software. Uncalibrated Optical Densities (O.D.) measures of
fluorescence signals were acquired with ImageJ4 or FIJI5. O.D.
values were obtained subtracting background signal from non-
stained tissue segments, and four different coronal sections were
used per sample.
2http://www.gimp.org/
3http://inkscape.org
4http://rsbweb.nih.gov/ij/
5http://fiji.sc/Fiji
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FIGURE 7 | Protein synthesis is modulated by DEX treatment in time-dependent manner. Puromycin tagging was employed in vivo in order to track translation
activity in situ. Mice received intranasal treatment of DEX or saline from 1 to 3 dpl and were subjected to puromycin (PURO) intranasal infusion 6 h after the DEX or
saline topical treatment at time-points 1, 2, and 3 dpl. The animals were euthanized 30 min thereafter and the tissue processed for immunofluorescence with
anti-puromycin antibody (A–L). Signal specificity was verified with CHX pre-treatment (M–O). Mean O.D. from OE sections labeled with antibody against PURO
(P) shows dramatic decrease in translation at 2 dpl. Results represent means ± SEM (n = 3). Dashed line represents mean O.D. of background staining in the
absence of PURO infusion. Red-dotted line represents mean O.D. of PURO incorporation in the presence of CHX. Two-way ANOVA [F (2,12) = 461, p < 0.0001 for
interaction between treatment and time] followed by a Tukey’s HSD multiple comparison test: significantly different (∗p < 0.05, ∗∗p < 0.001) from
methimazole-treated animals. Scale bars: 20 µm.
Statistical Analysis
Comparison of group means was performed using a one-
way ANOVA followed by a Tukey’s HSD procedure as
post hoc multiple comparisons test. Student’s t-test was
applied for comparison between two groups according to
homogeneity of variances (Levene’s test). Statistical analysis
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FIGURE 8 | Deregulation of S6K1 phosphorylation levels by DEX treatment to
the injured OE. Samples from methimazole-treated mice that received saline
or DEX intranasal infusion at 1 and 2 dpl were resolved in SDS–PAGE. The
proteins were transferred to PVDF membranes, which were probed for
phospho-S6K1 or eIF2α as loading controls (A). Densitometric analysis of
pS6K1 levels corrected for eIF2α and normalized against intact OE controls
(B) shows signal decrease at 2 dpl, similar to that of protein synthesis
(Figure 7). PCNA was used as an index of cell proliferation and loss of OMP
signal as control for lesion establishment (for each immunoblot β-actin was
used as loading control). Images are representative of n = 3 (each
independent sample was a pool from two mice). Image crop edition was
performed to enable lane grouping according to treatments (each
representative result showing six bands and the loading controls are from the
same membrane). Graphic results represent means ± SEM. Statistical
analysis revealed a significant interaction between the factors treatment (saline
or DEX) and time (1 or 2 dpl); F (1,8) = 6.888, p = 0.030.
was carried out with PSPP6 or STATISTICA 12 (StatSoft R©)
software. Analysis of neurosphere counting was performed with
nonparametric methods in R (R Core Team, 2017), using
Quade test for unreplicated complete block designs (each
independent experiment was considered an independent block)
and Quade post hoc test implemented in PMCMR package
(Pohlert, 2014) with Holm multiple-testing procedure. Data are
6https://www.gnu.org/software/pspp
represented as mean ± standard error of the mean (SEM),
except for neurosphere counting, which are represented as
median ± interquartile range (IQR) and plotted with ggplot2
functions (Wickham, 2009).
RESULTS
Topical DEX Co-infusion Prevents OE
Lesions Triggered by a Single Bolus LPS
Infusion
In order to evaluate topical DEX effects as anti-inflammatory
drug, we first developed a fast and reversible inflammatory lesion
model. Acute nasal infusion of 100 ng of LPS was able to produce
extensive OSNs loss 48 h after treatment, mainly at the ipsilateral
site of infusion, while saline infused OE remained intact (Figure 1
and Supplementary Figure S1). OMP staining failed to detect
mature OSNs in extensive areas of the OE from the LPS-treated
group. In addition, DAPI nuclear staining revealed remarkable
atrophy of the epithelium. Murine OE recovered rapidly after
lesion, since OSNs were considerably regenerated 14 days after
the infusion (Supplementary Figure S1). We must emphasize,
however, that depending on the conditions (e.g., different LPS
batches), the lesions were only reproducible at much higher doses
(1–5 µg/nostril) according to our experience. The variability
on LPS responses in nervous tissue has been recently discussed
(Goldstein et al., 2017). For the study reported here, we were able
to keep the same LPS dose (0.1 µg) for all in vivo protocols.
Dexamethasone co-treated animals showed dose-dependent
protection against the inflammatory insult as evaluated by OMP
staining and OE thickness measures (Figures 1A–P). Although
the LPS/DEX 80 ng/µl group showed some spots of OMP-
negative regions, the OE thickness remained largely preserved
compared to the OE from animals that did not receive the drug.
It is important to note that since DEX dose of 20 ng/µl only
provides modest protection to the OE, as shown by OE thickness
measures and lack of OMP preservation (Figures 1Q,R), our
subsequent studies were conducted with an intermediate dose of
40 ng/µl. This would be compatible with a strategy of keeping
DEX dosing as low as possible, ensuring the anti-inflammatory
effect in our experimental conditions.
Short-Term DEX Treatment After OE
Injury Impairs OSN Regeneration
Based on the histological analysis, lesions induced by LPS
were considered consistently established 48 h post-infusion.
Subsequently, we tested whether topical administration of DEX
could alter the course of OMP-positive cells reappearance 10 days
after LPS treatment by infusing the drug at Days 2, 3, and 4 after
LPS treatment. The comparisons were conducted at this stage
(i.e., 10 days after LPS infusion) because regeneration is only
partial (Supplementary Figure S1) and in consequence, it is more
flagrant to reveal treatment differences. As depicted in Figure 2,
intranasal bolus infusion of DEX (40 ng/µl) repeated for another
2 consecutive days lead to histological changes of the partially
regenerated OE. We could observe that tissue deformities, not
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found in the vehicle group, developed in every DEX-treated
animal during lesion recovery, mainly at the level of the septum.
Repeated DEX application after LPS lesion resulted in atrophic
OE, and in some cases, cellular changes included the incursions
from cells of the lamina propria. The atrophy also reflects marked
absence of OMP-positive cells, implying a failure in efficient new
OSNs generation in the injured region (Figure 2).
Taking advantage of a drug-induced model of OE lesion
(Brittebo, 1995), we also tested if DEX effects on neuronal
regeneration are reproducible in general models or if they
are specific for inflammatory lesions. Methimazole treatment
causes virtually total loss of OMP-positive neurons in the OE
(Figure 3). Two weeks after the drug treatment OSNs repopulate
the OE, albeit not completely, making it possible to measure
improvement or impairment of the regenerative process. Once
again, topical DEX (40 ng/µl) short-term treatment reduced
the overall reappearance of OMP-positive cells at the ipsilateral
site of infusion (Figures 3A–D). Interestingly, 1-day single DEX
infusion 24 h after the second injection of methimazole (1 dpl) is
not able to reproduce the effect observed with 3 days treatment
(Figures 3E,F). The animals from this group received saline
solution infusion at 2 and 3 dpl. Surprisingly, we observed a trend
for improvement in case of 1-day single treatment, since the OE
thickness from first-day-only DEX group was slightly larger than
methimazole group (Figure 3F).
DEX Treatment Interferes With OE
Neurogenesis Triggered by Injury
In order to perform fate mapping of cells generated in the course
of DEX treatment, the thymidine analog BrdU was incorporated
into dividing cells during methimazole lesion establishment and
DEX treatment. This strategy labels dividing progenitor cells
recruited by the OE injury stimulus, and in consequence, allows
the evaluation of DEX effects on cell proliferation, survival, or
differentiation. As shown in Figure 4, a smaller number of BrdU-
positive cells was observed in DEX-treated OE (Figures 4E–G)
when compared to non-treated control tissue (Figures 4B–D)
14 days after the second methimazole infusion (i.e., 14 dpl).
We further assessed BrdU-/OMP-double-labeling in order to
verify if DEX treatment could impair neuronal progenitor
differentiation or dramatically change cellular fate. We observed
predominance of OMP-/BrdU-double-labeled OSNs in both
DEX-treated and control animals (Figures 4D,G), indicating that
labeled progenitor cells differentiated into mature OSNs.
DEX Treatment Interferes With
Progenitor Cell Proliferation Without
Inducing TUNEL-Positive Cells
Since BrdU labeling revealed a dramatic decrease in the
number of OSNs derived from mitogenic activity during lesion
establishment and intranasal treatment, we next evaluated if DEX
interfered with cell division. The number of OE Ki-67+ cells
associated to basal lamina, the region populated by HBCs and
GBCs progenitors, were counted in order to reveal active cell
division associated with OSN replenishment (Figure 5). The
corticoid provoked a decrease in the number of Ki-67+ cells as
evaluated at the 3 dpl (6 h after the third DEX administration),
indicating reduced cell-cycling activity. In contrast, the analysis
of TUNEL-positive cells, a marker of DNA breaks suggestive of
apoptosis and other types of cell death, failed to reveal DEX effects
on cell death (Figure 6).
Protein Synthesis and S6-Kinase Are
Down-Regulated by DEX at Specific
Time-Points
The protein synthesis pathway is a key biological process
associated with cell proliferation. We connected the negative
effects of DEX treatment with protein synthesis using an in
situ approach to label nascent proteins/peptides with puromycin
(Starck et al., 2004). A similar strategy has showed strong
staining in cells with highly proliferative rates in intestine (Liu
et al., 2012). Puromycin labeling revealed a robust decrease in
translation following the second DEX infusion (Figures 7A–L,P).
Signal specificity was confirmed by the poor labeling when
the nostrils were treated with protein synthesis inhibitor CHX
(Figures 7M–O). A single DEX infusion is not able to promote
the same effect and showed the opposite trend, while the effect
magnitude of the third DEX infusion was milder than the
observed the second day (Figure 7P). In order to corroborate
the specific shutdown in translation at the second, but not
at the first day of DEX treatment, we verified the levels of
phosphorylated p70-S6 kinase (pS6K1), a downstream effector
molecule of the mTOR complex 1 (mTORC1) pathway, which
regulates protein synthesis and cell proliferation. As depicted
in Figure 8, S6K1 followed contrasting regulations comparing
the first and second consecutive day of DEX treatment. The
decrease in pS6K1 levels was only observed at the time-point
corresponding to the second DEX infusion. It is worth noting
the coincident increase or decrease in the PCNA levels, another
marker of cell division, according to treatment and time-point
that influenced the levels of S6K1 phosphorylation (Figure 8). In
addition, we also observed that repeated intranasal infusion of
rapamycin, an inhibitor of mTORC1, was detrimental to OSNs
recovery following methimazole-induced lesion (Supplementary
Figure S2).
In Vitro DEX Exposure Dose-Dependently
Interferes With OE Neuronal Progenitor
Activity Through GR
Since in vivo experiments cannot rule out indirect DEX effects,
even when infused locally, we performed in vitro assays using
neurosphere formation as a correlative index of progenitor cell
proliferation. Another advantage of this approach is to dissociate
GC effects from its anti-inflammatory activity. In essence,
immune cells are not representative cell types in this preparation.
We incubated the cell suspension with DEX at varied standard
concentrations and verified a dose-dependent decrease in
spheroid counting (Figures 9A,B,E). These neurospheres could
generate OMP-positive cells, independently of the treatment
(Figures 9C,D). We also verified if DEX mediated its effects
through GR using the antagonist mifepristone (RU486). In
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FIGURE 9 | In vitro generation of OE neurospheres recapitulates GR-mediated decrease in progenitor cell proliferation. Nasal mucosa from newborn mice were
pooled for each independent experiment, dissociated, and split in culture plates according to the indicated treatments. (A,B) Representative photomicrographs of
OE spheroids culture in the presence of growth factors and DEX, or its vehicle, for 7 div. (C,D) OMP immunostaining of differentiated cells derived from
neurospheres. OMP-positive cells were observed in both treatments. Spheroids counting were plotted for independent experiments as shown in E and F.
DEX dose-dependently reduced the number of OE neurospheres (E), an effect prevented by pre-incubation with GR antagonist RU486 (F). Data are represented as
median ± IQR. Statistical analysis was performed as replicated blocks (Quade test: F (3,9) = 14.5, p = 0.0008663 for data in E; F (4,12) = 14.6, p = 0.0001473 for
data in F) and comparison significance was adjusted with Holm method (∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.001 compared to control; †p < 0.05 compared to DEX
0.3 µg/ml; +p < 0.05 compared to DEX-RU486). Scale bar: (A,B) 100 µm; (C,D) 25 µm.
attempt to verify if membrane-associated GR was involved, DEX-
BSA was also used. RU486 was able to prevent, albeit not
completely, DEX effects on neurosphere formation (Figure 9F).
While DEX-BSA presented similar effects to DEX, we cannot
rule out that the complex is endocytosed with subsequent DEX
release, especially because the incubation time was long (up to
7 div; please refer to the section “Discussion”).
DISCUSSION
Here, we developed a fast inflammatory model of OE lesion,
which resembles the natural response to infections or acute
inflammatory insults to the nasal mucosa. The ability of this
bacterial toxin to cause extensive neuronal damage is in contrast
to the fact that even higher LPS doses are in general not harmful
to neuronal cells in the CNS (Szczepanik et al., 1996; Glezer
et al., 2003b; Nadeau and Rivest, 2003). Very recently, another
study showed that repeated LPS intranasal infusion (µg range)
promoted rhinitis that damaged synaptic connection to the
olfactory bulb (Hasegawa-Ishii et al., 2017), which is in agreement
with the lesion results reported in this study.
As expected, DEX prevented LPS effects due to its notorious
anti-inflammatory effects (Pang et al., 2012), including its
previously shown ability to downregulate NF-κB activation in the
brain (Glezer et al., 2003a). Although a detailed dose–response
curve would be required in order to determine the minimal
DEX effective dose, it is reasonable to suppose that the higher
dose (80 ng/µl; ∼155 µM of sodium DEX–phosphate) used
in our study is compatible with a therapeutic range, since the
lower dose (20 ng/µl) failed to prevent inflammatory-induced
loss of OMP staining. In addition, DEX intranasal aqueous
spray preparation designed to deliver 800 µg/day in humans
(Martino et al., 2015), as well DEX commercial ophthalmic
preparations, contains 1 µg/µl of the drug, which is more than
10 times concentrated than the higher dose used in our study.
Although 80 ng/µl would be therapeutically relevant, we selected
an intermediate dose of 40 ng/µl to assess DEX effects in the
course of neuronal regeneration.
The OE is quite efficiently repaired 14 days after the
inflammatory stimulus, which is in agreement with the fast
neuronal regeneration observed in a transgenic model of
reversible chronic rhinosinusitis (Lane et al., 2010). Hence,
we analyzed the time-point of 10 days post-infusion (LPS) to
better access different degrees of OSN regeneration. Indeed,
striking differences were observed when DEX was infused 2, 3,
and 4 days after LPS infusion. It is possible that this period
is critical for organizing regenerative responses that are in
some way compromised by DEX treatment. Interestingly, a
recent study showed that inflammation-driven NF-κB activity
is necessary for OE regeneration (Chen et al., 2017). Therefore,
we investigated whether the drug effect is mediated through its
anti-inflammatory effects or other mechanisms, GR-dependent
or not.
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Methimazole has been widely used to induce reproducible
OSN loss and offers a straightforward paradigm to test the
DEX effects (Murray and Calof, 1999; Leung et al., 2007;
Chen et al., 2017). In this case, DEX effects could be analyzed
by infusing the drug when the lesion was definitively and
uniformly established throughout the entire OE. It is important
to note that the OE takes a longer time to regenerate after
methimazole administration when compared to LPS infusion.
Despite this dissimilarity and the different nature of the
damages, DEX effects on neuronal regeneration were comparable
between the lesion models. This implies that specific cellular
dynamics involved particularly in LPS or inflammatory lesion
models does not account solely for the observed effects of
the steroid. It is therefore more likely that the presence of
the drug in a specific period, shortly after the lesion, is the
underlying cause that hampers repair mechanisms in the OE.
The fast organization of both proliferative and fate determining
transcriptional changes has been previously reported during
OE recovery after bulbectomy (Shetty et al., 2005), and closely
resembles the period in which DEX was infused. Our data
also suggest that topic DEX administration must be recurrent
during this crucial stage in order to interfere with OSNs
replenishment. However, it remains to be determined whether
repeated administrations or DEX topic delivery at specific time-
points after lesion explains the dramatic effects of the steroid on
OE regeneration.
Fate analysis of cells derived from BrdU-labeled progenitors
revealed a reduced number of labeled cells in the OE after a
short-term DEX 3-days treatment. Our results indicate that
DEX short-term treatment does not halt the differentiation
process, since both fate-mapping and in vitro results indicate
that DEX-treated progenitor cells can differentiate into OSNs.
The reduced number of regenerated OSNs can be a net result
of diminished proliferation of progenitor cells or increased
cell death. One study showed that GCs promote apoptosis
in the OE (Dorscheid et al., 2003), while in another study
this effect was curiously associated with a better regeneration
of the OE (Takanosawa et al., 2009). Our results point to a
different effect, which we believe may reflect the accuracy
of our model. Reduction of Ki-67+ cells after DEX 3-days
treatment and failure in detecting increased TUNEL staining
during the 3 days of steroid treatment strongly suggests
that GCs main effect is on progenitor cell proliferation.
We also corroborated the effect in vitro, excluding DEX
anti-inflammatory mechanisms from our observations. We
further explored associated cellular changes and found
a profound reduction in protein synthesis caused by the
second DEX infusion at 2 dpl. A remarkable correlation was
found with pS6K1 levels, a mTORC1 downstream effector
molecule involved in protein synthesis through S6 ribosomal
protein phosphorylation and cell proliferation (Saxton and
Sabatini, 2017). Interestingly, genetically driven activation
of mTOR pathway favors axonal regeneration in a model
of optic nerve injury (Park et al., 2008). Here, we propose
that mTOR pathway activation could be explored for OE
function preservation, since DEX modulates mTORC1
targets (Figures 7, 8) and rapamycin interferes with OSNs
replenishment after methimazole lesion (Supplementary
Figure S2).
Delay in olfactory function recovery is a risk factor for
olfactory loss (London et al., 2008). Even more, DEX and
GCs have been shown to interfere with neurogenesis in
other models (Kim et al., 2004; Schroter et al., 2009; Yu
et al., 2010), which is in agreement with our findings.
Interestingly, a clinical study found remarkable differences in
the outcomes of topical steroid-treated patients versus those
receiving systemic treatment. It has also been reported that
systemic GCs are beneficial to OE regeneration or olfactory
nerve recovery (Carbone et al., 2003; Heilmann et al., 2004;
Kapucu et al., 2012). The route of administration seems
to be very important for reproducing DEX effects, which
appears to be hazardous to neuronal recovery independently
of the OE lesion model. Here, we also explored DEX
effects in vitro, which supports cell-autonomous mechanisms.
The effects were GR-dependent since the antagonist largely
prevented reduction in progenitor activity. While a membrane-
associated GR has been implicated in DEX non-genomic effects
on neural precursor cells (Samarasinghe et al., 2011), we
cannot assure that DEX-BSA was not processed and released
the GC. This possibility remains to be verified in future
studies.
CONCLUSION
Our study supports that the safety of topical steroidal anti-
inflammatory drugs must be further evaluated in terms
of olfactory function recovery. DEX, selected here as a
representative drug to explore its impact on regenerative
outcomes, is able to abrogate important repair mechanisms
of the OE. Although GCs are important for controlling the
inflammatory component of rhinosinusitis, a risk-benefit analysis
must account the systemic side-effects of this class of drug and the
possibility of anosmia and hyposmia development over recurrent
treatments.
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